Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Phase 2

3(60.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

N/A(1)

Loading network data...

Showing 5 of 5 trials

A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

Role: collaborator

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Role: collaborator

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Role: lead

Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE

Role: collaborator

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

Role: lead

All 5 trials loaded